Cargando…
Serum-Based Biomarkers in Neurodegeneration and Multiple Sclerosis
Multiple Sclerosis (MS) is a debilitating disease with typical onset between 20 and 40 years of age, so the disability associated with this disease, unfortunately, occurs in the prime of life. At a very early stage of MS, the relapsing-remitting mobility impairment occurs in parallel with a progress...
Autor principal: | LoPresti, Patrizia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138270/ https://www.ncbi.nlm.nih.gov/pubmed/35625814 http://dx.doi.org/10.3390/biomedicines10051077 |
Ejemplares similares
-
Silent Free Fall at Disease Onset: A Perspective on Therapeutics for Progressive Multiple Sclerosis
por: LoPresti, Patrizia
Publicado: (2018) -
The Selective HDAC6 Inhibitor ACY-738 Impacts Memory and Disease Regulation in an Animal Model of Multiple Sclerosis
por: LoPresti, Patrizia
Publicado: (2019) -
Tau in Oligodendrocytes Takes Neurons in Sickness and in Health
por: LoPresti, Patrizia
Publicado: (2018) -
HDAC6 in Diseases of Cognition and of Neurons
por: LoPresti, Patrizia
Publicado: (2020) -
Neurodegeneration in multiple sclerosis
por: Mey, Gabrielle M., et al.
Publicado: (2022)